Your browser doesn't support javascript.
loading
Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed.
Soto, E; Staab, A; Freiwald, M; Munzert, G; Fritsch, H; Döge, C; Trocóniz, I F.
Affiliation
  • Soto E; Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain. elena.soto@pfizer.com
Clin Pharmacol Ther ; 88(5): 660-7, 2010 Nov.
Article in En | MEDLINE | ID: mdl-20927084
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Computer Simulation / Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Models, Biological / Neutropenia Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2010 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Computer Simulation / Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Models, Biological / Neutropenia Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2010 Document type: Article Affiliation country: Country of publication: